None
Quote | Xynomic Pharmaceuticals Holdings Inc. (NYSE:XYN)
Last: | $ |
---|---|
Change Percent: | 0.00% |
Open: | $N/A |
Close: | $2.95 |
High: | $N/A |
Low: | $N/A |
Volume: | 0 |
Last Trade Date Time: | 07/17/2019 04:55:09 pm |
News | Xynomic Pharmaceuticals Holdings Inc. (NYSE:XYN)
Deals and Financings Vivo Capital, a US-China healthcare investment firm, has raised $1.28 billion for its ninth fund, bringing its assets under management to more than $4.3 billion. Vivo invests in all stages of healthcare companies, from start-up to publicly owned. Founded in 1996, Vivo ...
RALEIGH, N.C. and SHANGHAI, June 12, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, Nasdaq: XYN), a clinical stage US-China oncology drug development company, announced that it recently held a pre-IND meeting with the U.S. Food and Drug Admin...
Message Board Posts | Xynomic Pharmaceuticals Holdings Inc. (NYSE:XYN)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Xynomic Pharmaceuticals Holdings Inc. Company Name:
XYN Stock Symbol:
NYSE Market:
RALEIGH, N.C. and SHANGHAI, June 12, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, Nasdaq: XYN), a clinical stage US-China oncology drug development company, announced that it recently held a pre-IND meeting with the U.S. Food and Drug Admin...
RALEIGH, N.C. and SHANGHAI, June 06, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, Nasdaq: XYN), a clinical stage US-China oncology drug development company, announced that Xynomic has dosed the first patient in a Phase 1/2 trial that combin...
RALEIGH, N.C. and SHANGHAI, May 21, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”), a clinical stage US-China oncology drug development company (Nasdaq: XYN), announced today that long-term follow up data of exceptional responders to abexinos...